Montana Medicaid GLP-1 Coverage 2026: Pattern #46 — Categorical Weight-Loss-Medication Exclusion After HB 245 Made Expansion Permanent and SB 417 (Anti-Obesity Drug Mandate) Died on an 11-1 Senate Committee Vote — PA Processed by Mountain-Pacific Quality Health, a Non-Profit QIO, Within One of Approximately 6 PCCM (Passport to Health) States

TL;DR — what Montana Medicaid covers and does not cover

The categorical exclusion is anchored verbatim on the DPHHS Pharmacy Program page:

“Not Covered: Unapproved drugs, experimental medications, fertility drugs, weight-loss medications, cosmetic treatments, erectile dysfunction drugs, and non-formulary OTC drugs.”

The Montana Medicaid Prescription Drug Program Manual reinforces the policy:

“The program explicitly does not reimburse for drugs prescribed for weight reduction.”

What MT Medicaid does NOT cover (excluded under the categorical AOM bundle):

• Wegovy (semaglutide) for obesity
• Zepbound (tirzepatide) for obesity
• Saxenda (liraglutide) for obesity
• Imcivree (setmelanotide)
• Qsymia (phentermine/topiramate)
• Contrave (naltrexone/bupropion)
• Orlistat (over-the-counter and prescription)
• Phentermine (Adipex-P, Lomaira, generic)
• Compounded semaglutide and compounded tirzepatide (excluded as “unapproved drugs”)

What MT Medicaid covers for T2D-indicated use (subject to PA via MPQH; specific PDL criteria UNVERIFIED in this article):

• Ozempic (semaglutide) for T2D
• Mounjaro (tirzepatide) for T2D
• Trulicity (dulaglutide) for T2D
• Victoza (liraglutide) for T2D
• Rybelsus (semaglutide tablets) for T2D
• Exenatide (Byetta, generic) for T2D

UNVERIFIED carve-outs (MPQH has posted PA criteria PDFs but the documents returned as redirect/binary in WebFetch and direct download was required for verbatim quotation as of May 15, 2026):

• Wegovy MACE / MASH carve-out (MPQH PA criteria URL mpqhf.org/download/25789/) — status UNVERIFIED
• Zepbound OSA carve-out (MPQH PA criteria URL mpqhf.org/download/26184/) — status UNVERIFIED

Architectural distinctive features:

• PCCM (Passport to Health), not MCO architecture — one of approximately 6 states still on FFS + PCCM. No MCO formulary variation. One statewide PDL via DPHHS + MPQH.
• HB 245 (2025) ended the sunset on expansion — eliminated a source of churn risk that had accompanied Medicaid expansion in Montana since 2015.
• SB 417 (2025) AOM mandate died 11-1 in committee — first Montana legislative attempt at an anti-obesity drug coverage mandate; Sen. Ellie Boldman (D-Missoula) likely to refile in 2027.
• HB 245 + SB 417 split tells a clear policy story — Montana expanded permanence of WHO is covered, but explicitly did NOT expand WHAT is covered for AOM.
• IHS / tribal overlap — one of the largest per-capita IHS Medicaid populations in the country (~20,091 AI/AN expansion enrollees April 2023). IHS facilities draw 100% FMAP but the AOM exclusion still applies.
• Sparse-geography access — among lowest US states for endocrinologist and bariatric medicine density. Mail-order pharmacy is operationally important even where coverage exists.
• MPQH is a non-profit QIO, NOT a commercial PBM — PA appeals escalate directly to DPHHS without a commercial-PBM intermediary layer.

Pharmacy benefit architecture:

• PA processor: Mountain-Pacific Quality Health (MPQH) Drug PA Unit
• Phone: (800) 395-7961 or (406) 443-6002
• Fax: (800) 294-1350 or (406) 513-1928
• Mail: MPQH Drug PA Unit, P.O. Box 5119, Helena, MT 59604
• Office: 50 W 14th St, Ste. 5, Helena, MT 59601
• Hours: 8 a.m.–5 p.m. Mountain Time, Mon-Fri
• PA form: “Request for Drug Prior Authorization” at medicaidprovider.mt.gov/docs/forms/prescripdrugpriorauthreq.pdf
• Single PDL: applies uniformly across FFS (no MCO formulary variation)

1. Federal authority: 42 U.S.C. § 1396r-8(d)(2)(A)

The federal Medicaid drug rebate statute at 42 U.S.C. § 1396r-8(d)(2)(A) grants states an optional authority to exclude “agents when used for anorexia, weight loss, or weight gain” from coverage. Montana has exercised this authority at the DPHHS Pharmacy Program policy level, with the exclusion bundled alongside fertility drugs, cosmetic treatments, erectile dysfunction drugs, and non-formulary OTC drugs in a single “Not Covered” bucket.

Unlike Maine Pattern #39 (which anchors the exclusion in a freestanding state regulation at 10-144 C.M.R. ch. 101, Ch. II, § 80.06(A)) or Mississippi Pattern #35 (which executes a State Plan Amendment carve-back-in via SPA 23-0013), Montana operates the exclusion at the DPHHS policy level only. There is no Montana Administrative Rule specifically naming weight-loss drugs as a separate excluded class — the DPHHS Pharmacy Program webpage and Prescription Drug Program Manual are the primary publicly accessible statements of the policy.

2. DPHHS Pharmacy Program: the categorical exclusion verbatim

The Montana Department of Public Health and Human Services maintains the binding statement of pharmacy coverage policy on the DPHHS Pharmacy Program page (dphhs.mt.gov/montanahealthcareprograms/medicaid/pharmacy). The “Not Covered” bucket reads verbatim:

“Not Covered: Unapproved drugs, experimental medications, fertility drugs, weight-loss medications, cosmetic treatments, erectile dysfunction drugs, and non-formulary OTC drugs.”

The Montana Medicaid Prescription Drug Program Manual (medicaidprovider.mt.gov/manuals/prescriptiondrugprogrammanual) reinforces the policy:

“The program explicitly does not reimburse for drugs prescribed for weight reduction.”

Two verbatim statements at two different DPHHS-owned URLs eliminate ambiguity: Montana Medicaid categorically excludes weight-loss medications. The bundled-exclusion framing (weight-loss + fertility + cosmetic + ED + non-formulary OTC) is stylistically pre-ACA and is consistent with the federal Medicaid drug rebate statute’s optional-exclusion list. Montana is NOT in the KFF January 2026 13-state cohort of states covering GLP-1s for obesity (KFF tracker).

3. Mountain-Pacific Quality Health: PA processor and contact architecture

Mountain-Pacific Quality Health (MPQH) is a non-profit Quality Improvement Organization headquartered in Helena, Montana. MPQH is contracted by DPHHS to administer the Montana Medicaid Drug Prior Authorization Program. Importantly, MPQH is not a commercial pharmacy benefit manager like Express Scripts, CVS Caremark, or OptumRx — the structurally distinctive feature is that PA appeal escalations route directly to DPHHS without a commercial-PBM intermediary layer.

3.1 MPQH Drug PA Unit contact information

• Phone: (800) 395-7961 or (406) 443-6002
• Fax: (800) 294-1350 or (406) 513-1928
• Mail: MPQH Drug PA Unit, P.O. Box 5119, Helena, MT 59604
• Office: 50 W 14th St, Ste. 5, Helena, MT 59601
• Hours: 8 a.m.–5 p.m. Mountain Time, Monday-Friday
• MPQH Drug Prior Authorization service page: mpqhf.org/our-services/pharmacy-services/drug-prior-authorization/
• MPQH Pharmacy Resources hub: mpqhf.org/resources/pharmacy-resources/
• MPQH Montana Medicaid Pharmacy hub: mpqhf.org/corporate/montanans-with-medicaid/pharmacy/

3.2 The “Request for Drug Prior Authorization” form

The single PA form governing Montana Medicaid drug prior authorization is titled “Request for Drug Prior Authorization” and is published by DPHHS at medicaidprovider.mt.gov/docs/forms/prescripdrugpriorauthreq.pdf. Unlike multi-form architectures (e.g., Vermont’s Semaglutide MACE/MASH PA Form + Zepbound OSA PA Form + General PA Form trio), Montana uses one master form for all drug PA submissions.

3.3 PA turnaround verbatim

Per the Montana Medicaid Prescription Drug Program Manual:

“Requests are typically decided immediately; special circumstances receive decisions within 24 hours.”

This is one of the fastest documented PA turnaround windows in the 50-state series — the “decided immediately” language is operationally distinctive. Most state Medicaid PA programs document a 24-72 hour standard window with longer holds for incomplete submissions; Montana’s manual language commits to immediate decisions on routine requests with a 24-hour cap for special circumstances.

4. HB 245 (2025): Medicaid expansion made permanent

4.1 The bill: Rep. Ed Buttrey, signed March 27, 2025

HB 245 was sponsored by Rep. Ed Buttrey (R-Great Falls). The bill was signed into law by Gov. Greg Gianforte on March 27, 2025, without a press release. The enactment was reported by Montana Free Press (Montana Free Press, March 28, 2025).

4.2 The effect: first state to convert sunsetting expansion to non-sunsetting

HB 245 eliminated the recurring sunset clause that had accompanied Montana Medicaid expansion since the original 2015 enactment. Montana’s expansion (branded the HELP Program — Health and Economic Livelihood Partnership) had previously been subject to legislative reauthorization on a multi-year cadence; HB 245 made expansion permanent, eliminating the source of legislative churn that had accompanied the program for a decade.

Montana thereby became the first state to convert a previously sunset-conditioned Medicaid expansion into a non-sunsetting permanent program. The expansion population (adults 18-65 up to 138% FPL) totaled 75,318 enrollees as of June 2025 per DPHHS public reporting, with federal/state cost-sharing at 90%/10% and a state share of approximately $100 million annually.

4.3 What HB 245 did NOT do

HB 245 made no change to the categorical anti-obesity-medication exclusion that operates at the DPHHS Pharmacy Program and Prescription Drug Program Manual level. The bill addressed Medicaid eligibility permanence (WHO is covered) but did not touch the pharmacy benefit scope (WHAT is covered). This is operationally important: a new Medicaid expansion enrollee in June 2025 has the same categorical AOM exclusion as a long-tenured traditional Medicaid beneficiary — HB 245 expanded the permanence of the coverage relationship but did not add anti-obesity drugs to the formulary.

5. SB 417 (2025): the AOM mandate that died 11-1 in committee

5.1 The bill: Sen. Ellie Boldman, “Generally revise laws relating to insurance coverage relating to obesity prevention”

SB 417 was sponsored by Sen. Ellie Boldman (D — District 47, Missoula) in the 2025 Montana Legislative Session. The bill title verbatim:

“Generally revise laws relating to insurance coverage relating to obesity prevention.”

SB 417 would have mandated state-regulated insurance coverage for anti-obesity medications, including in Medicaid. It represented the first Montana legislative attempt to mandate AOM coverage and was framed in line with peer-state proposals (e.g., Vermont’s H.765/S.164 (2024), Maine’s LD 480 (2025), and Nebraska’s LB907 (2024)).

5.2 The 11-1 tabling vote

On March 1, 2025, the Senate Business, Labor and Economic Affairs Committee tabled SB 417 on an 11-1 vote. The bill formally died in process on May 23, 2025 per the Montana Legislature’s bill tracker (bills.legmt.gov; secondary tracker fastdemocracy.com).

The 11-1 tabling vote is decisive in committee context (only one vote of dissent against tabling). It indicates broad bipartisan opposition to the AOM coverage mandate among the committee membership rather than a narrow partisan or fiscal-only objection. The fiscal pressure analogous to other state estimates (Vermont $75M annual, Nebraska $42.4M, Maine $42-53M) likely contributed, but the magnitude of the vote suggests substantive committee opposition beyond fiscal concerns alone.

5.3 The WHO-vs-WHAT split with HB 245

The HB 245 + SB 417 pairing in the same legislative session tells a clear policy story:

• HB 245 (signed March 27, 2025) — expanded permanence of WHO is covered by Medicaid by eliminating the recurring sunset on the HELP Program.
• SB 417 (tabled 11-1 March 1, 2025; died May 23, 2025) — would have expanded WHAT is covered by mandating AOM coverage in state-regulated insurance and Medicaid. Did not advance.

Montana’s 2025 legislative outcome thus represents a clean WHO-vs-WHAT split. No other state in the 50-state series ran a parallel split this cleanly in a single session. The headline framing is operationally precise: Montana expanded permanence of who is covered by Medicaid, but explicitly did NOT expand what is covered for anti-obesity medications.

5.4 2027 refile probability

Montana’s legislative sessions are biennial (every odd-numbered year). The next session convenes January 2027. Sen. Ellie Boldman has not formally announced a 2027 refile as of May 15, 2026, but historically committee-tabled bills with narrow partisan support tend to be refiled by the same sponsor or a successor Democratic sponsor in the next biennial cycle. The fiscal pressure that drove the 11-1 vote will likely intensify by 2027 given continued GLP-1 utilization growth across all payer types. Readers should track bills.legmt.gov as the 2027 session approaches.

6. PCCM architecture: Passport to Health, not capitated MCOs

6.1 Passport to Health (1993–present)

Montana’s Medicaid delivery system has operated as fee-for-service (FFS) with a Primary Care Case Management (PCCM) overlay since 1993. The PCCM program is branded Passport to Health (dphhs.mt.gov/MontanaHealthcarePrograms/Passport). Under Passport to Health, each Medicaid beneficiary selects a primary care provider (the “Passport provider”) who serves as a case manager for the patient’s care navigation but does not bear full insurance risk for the cost of care.

6.2 BCBSMT expansion contract ended end of 2017

Blue Cross Blue Shield of Montana (BCBSMT) held an expansion-era contract from the HELP Program launch through the end of 2017, when DPHHS terminated the contract. Since 2018, Montana has operated without any full-risk capitated Medicaid managed care organization. Montana is therefore one of approximately 6 states still using PCCM rather than capitated MCO managed care.

6.3 Implications for GLP-1 coverage

The PCCM-not-MCO architecture has direct implications for GLP-1 coverage policy:

• One statewide PDL via DPHHS + MPQH. No MCO-specific formulary variation. A Montana Medicaid beneficiary in Kalispell, Billings, Missoula, or any reservation pharmacy faces the same categorical AOM exclusion and the same MPQH PA pathway.
• No MCO appeal layer. In MCO states, PA denials typically route through the MCO’s internal appeal process before reaching the state fair hearing. In Montana, denials route directly from MPQH to DPHHS administrative review and then to a DPHHS Office of Administrative Hearings fair hearing.
• Policy lever is at DPHHS. The path to expanding GLP-1 coverage in Montana is through DPHHS policy change (via the Pharmacy Program and Prescription Drug Program Manual) or through state legislation (e.g., a successor to SB 417). There is no MCO-contract negotiation pathway that could expand coverage in Montana while DPHHS’s exclusion remains in place.
• KFF cohort exclusion follows architecturally. Because the single statewide PDL excludes weight-loss medications, Montana cannot appear in the KFF 13-state coverage cohort without a DPHHS-level policy reversal or a legislative mandate.

7. Appeals pathway: DPHHS Office of Administrative Hearings under Mont. Admin. R. 37.5.310

Montana Medicaid uses a two-step appeals architecture administered by the DPHHS Office of Administrative Hearings (Quality Assurance Division). The hearings office address is P.O. Box 202953, Helena, MT 59620-2953; phone 406-444-2470. Hearings are held via Zoom (computer, smartphone, or phone-in — see DPHHS Office of Administrative Hearings FAQ).

7.1 Beneficiary-side filing deadlines

Beneficiary-side filing deadlines verbatim (DPHHS / Cover Montana / Montana Lawhelp consolidated guidance):

“Most appeals must be filed within 15 days of the date of the Order you are appealing. Some cases allow 30 days to appeal.”

“You have 90 days from the date of the written notice telling you about the adverse action to ask for an Administrative Hearing.”

The 15-day standard window with a 90-day outer cap is operationally distinctive in the 50-state series. Most peer states publish a 30-, 60-, or 90-day standard window (e.g., Vermont’s 60-day DVHA internal appeal + 120-day Human Services Board fair hearing; Rhode Island’s 120-day MCO appeal). Montana’s 15-day standard window requires fast action by beneficiaries upon receipt of an adverse action notice.

7.2 Provider-side per Mont. Admin. R. 37.5.310

The binding provider-side appeals regulation is Mont. Admin. R. 37.5.310 (Cornell Law / Montana Administrative Rules). Verbatim:

“Administrative Review Request: must be received by the department within 30 days of mailing of the department’s written determination.”

“Fair Hearing Request: must be received not later than the 30th calendar day following the date of the department’s written administrative review determination.”

[Hearing officer must render] “a written proposed decision within 90 calendar days.”

Provider-side appeals therefore use a 30-day + 30-day staged window: 30 days from determination mailing to file the Administrative Review Request, then 30 days from the administrative review decision date to file the Fair Hearing Request, then a 90-day window for the hearing officer’s written proposed decision. This is more generous than the beneficiary-side 15-day window but still requires prompt provider action upon receipt of adverse determinations.

7.3 Continuation of benefits

Continuation of benefits during appeal is automatic unless the claimant opts out. Verbatim:

“Unless the claimant specifically states they do not want continued benefits, benefits are automatically continued at the same benefit level (reinstated) until the hearing decision when the hearing request is filed between the date the adverse action notice is mailed and the adverse action effective date.”

This is an opt-out-not-opt-in continuation regime, which is more protective of beneficiaries than peer-state regimes that require explicit affirmative request for aid-paid-pending (e.g., Vermont’s DVHA internal appeal where aid-paid-pending must be requested at the time of appeal filing).

7.4 Federal/state cycle time

Per the DPHHS FAQ:

“Federal and state laws require all cases to be finalized in 60-90 days.”

The 60-90 day federal/state cycle aligns with the 42 CFR 431.244(f)(1) standard 90-day cycle for Medicaid fair hearings. Expedited cycle times for urgent medical need are UNVERIFIED for Montana specifically (federal floor is 72 hours per 42 CFR 431.244(f)(2) for cases involving immediate or serious threat to life or health).

7.5 Practical denial-recovery strategy

1. First, call the MPQH Drug PA Unit at (800) 395-7961. Many denials are documentation deficiencies recoverable via re-submission of the same PA form with additional clinical evidence.
2. If the denial is substantive (criteria-based), re-submit the PA form with stronger evidence. For T2D-indicated GLP-1 denials, add baseline HbA1c, recent HbA1c, prior medication history with metformin and other relevant classes, and the clinical rationale for GLP-1 selection.
3. If re-submission fails, file the beneficiary-side administrative hearing request within 15 days (or 30 days in cases where the longer window applies). Continuation of benefits is automatic unless you opt out.
4. For provider-side disputes, file the Administrative Review Request within 30 days of mailing of the department’s written determination. If administrative review fails, file the Fair Hearing Request within 30 days of the administrative review determination.
5. Contact Cover Montana (covermt.org/fair-hearings-and-administrative-review/) or Montana Lawhelp (montanalawhelp.org) for beneficiary representation guidance.

8. IHS / tribal-pharmacy overlap: one of the largest per-capita AI/AN Medicaid populations

Montana has one of the largest per-capita Indian Health Service (IHS) populations in the country among Medicaid beneficiaries. Approximately 20,091 AI/AN expansion enrollees as of April 2023 per the Montana Budget and Policy Center “Medicaid Expansion in Indian Country” report (montanabudget.org). The seven federally recognized tribes in Montana (Blackfeet, Confederated Salish and Kootenai, Crow, Fort Belknap, Fort Peck, Northern Cheyenne, and Little Shell Chippewa-Cree) plus the urban Indian health programs serve a large Medicaid-enrolled AI/AN population.

100% FMAP for IHS facilities. Services rendered to AI/AN Medicaid beneficiaries at IHS facilities (whether direct IHS, tribal 638-contract, or urban Indian) draw 100% Federal Medical Assistance Percentage — the state pays no share. Tribal members enrolled in Medicaid pay no premiums or copays.

The AOM exclusion still applies. Despite the 100% FMAP and zero-cost-share advantages for AI/AN Medicaid beneficiaries, the categorical anti-obesity-medication exclusion still applies to drugs dispensed through IHS-Medicaid billing pathways. A Montana Medicaid-enrolled AI/AN beneficiary at a Blackfeet, Fort Peck, or urban Indian pharmacy faces the same DPHHS Pharmacy Program exclusion of weight-loss medications.

UNVERIFIED: Whether tribally operated 638-contract pharmacies have separate formulary access or AOM-coverage flexibility distinct from the DPHHS PDL is not addressed in the publicly accessible Montana Medicaid IHS Provider materials (medicaidprovider.mt.gov/57). Readers should consult the DPHHS Tribal Consultation page (dphhs.mt.gov/medicaidtribalconsultation) for jurisdiction-specific guidance.

9. Sparse-geography access: mail-order pharmacy dominates

Montana ranks among the lowest US states for endocrinologist density and bariatric medicine density per capita. The state covers 147,040 square miles with a total population of approximately 1.1 million — a population density of about 7 people per square mile (versus the US average of 94). Even if Montana Medicaid covered GLP-1s for obesity, last-mile access (PCP-issued prescription, mail-order pharmacy delivery, telehealth specialist consultation) would dominate over in-person specialist access.

Operational implications for Montana patients:

• PCP-issued GLP-1 is often the most accessible route for both T2D-indicated coverage and cash-pay obesity-indicated use. Specialty endocrinology consultation typically requires travel to Billings, Missoula, Bozeman, or Great Falls.
• Mail-order pharmacy is operationally important even for in-state covered prescriptions. Montana Medicaid’s preferred mail-order pharmacy networks should be confirmed with MPQH (800-395-7961) before assuming any specific pharmacy is in-network.
• Telehealth specialist consultation via licensed Montana providers can substitute for in-person endocrinology or sleep medicine visits in many cases. The Montana Medical Association maintains a directory of in-state telehealth-capable specialists.
• Cash-pay direct-to-consumer GLP-1 (NovoCare, LillyDirect, LegitScript-approved compounded telehealth) is operationally important in Montana given sparse-geography access. Direct shipping to rural addresses is generally available; verify with the specific manufacturer or telehealth platform.

10. T2D-indicated GLP-1 coverage (UNVERIFIED specific criteria)

Type 2 diabetes-indicated GLP-1 receptor agonists (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Exenatide) are covered under the Montana Medicaid standard preferred drug list with prior authorization processed by Mountain-Pacific Quality Health (MPQH). The DPHHS Pharmacy Program “Not Covered” bucket excludes “weight-loss medications” but does not exclude T2D-indicated GLP-1 use — the exclusion is indication-specific to weight reduction, not molecule-specific.

Specific T2D PA criteria are UNVERIFIED in this article (preferred vs. non-preferred status, HbA1c thresholds, step-therapy requirements, quantity limits) due to PDL PDF binary corruption in WebFetch during verification on May 15, 2026. The May 1, 2026 PDL URL (medicaidprovider.mt.gov/docs/pharmacy/2026/May2026PreferredDrugList.pdf) and January 15, 2026 PDL URL (medicaidprovider.mt.gov/docs/pharmacy/2026/January2026508CompliantBlackPDL.pdf) should be downloaded directly for operative criteria.

Prescriber documentation checklist for T2D-indicated GLP-1 PA submission to MPQH (synthesized from general Medicaid PA standards; specific Montana criteria UNVERIFIED):

• T2D diagnosis with ICD-10 code (E11.x for Type 2 diabetes mellitus)
• Baseline HbA1c and most recent HbA1c (preferably within 90 days)
• Prior medication history including metformin trial and outcome (most Medicaid plans require metformin failure or intolerance as a step-therapy prerequisite)
• Trial history with second-line classes (sulfonylurea, DPP-4 inhibitor) if relevant
• Clinical rationale for GLP-1 class selection (cardiovascular risk, renal protection, weight comorbidity, hypoglycemia avoidance)
• Specific drug requested and dosing (preferred vs. non-preferred per MT PDL)
• Documentation of any prior failures with preferred alternatives if requesting a non-preferred drug

11. Enrollment context: 210,942 total Medicaid + CHIP across one statewide PDL

Total Montana Medicaid + CHIP enrollment was approximately 210,942 as of October 2025 per healthinsurance.org. Subpopulation breakdown:

• Medicaid Expansion (HELP Program): 75,318 enrollees as of June 2025 per DPHHS public reporting. Adults 18-65 up to 138% FPL. Funded 90% federal / 10% state; state share approximately $100 million annually.
• AI/AN expansion enrollees: approximately 20,091 as of April 2023 per the Montana Budget and Policy Center “Medicaid Expansion in Indian Country” report — one of the largest per-capita AI/AN Medicaid populations in the country.
• Traditional Medicaid + Healthy Montana Kids + Healthy Montana Kids Plus: the balance of the 210,942 total, including TANF-related adults, parents, pregnant women, children, blind/disabled, and aged populations.

The HELP Program (Health and Economic Livelihood Partnership) is the operational brand of Montana’s ACA Medicaid expansion. HB 245 (signed March 27, 2025) eliminated the recurring sunset on HELP, making the expansion non-sunsetting. Healthy Montana Kids (HMK) is the CHIP component for children up to 261% FPL; HMK Plus is the Medicaid-funded children’s coverage for children below the HMK income threshold.

The chronic-weight-management exclusion applies uniformly across the entire 210,942-person Medicaid + CHIP population regardless of eligibility pathway. There is no expansion-vs-traditional formulary distinction, no MCO-specific formulary deviation, and no HMK-specific carve-out that creates a different pharmacy benefit for any subpopulation. The unified DPHHS + MPQH PDL applies to every Montana Medicaid pharmacy claim regardless of where the beneficiary lives, what their eligibility category is, or which Passport to Health primary care provider they have selected.

Live current May 2026 enrollment is UNVERIFIED in this article. The DPHHS Medicaid Enrollment Dashboard (Tableau dashboard) provides live data but the specific May 2026 figure was not extracted in this verification. The 210,942 October 2025 figure is the most current verified total as of publication.

12. The HB 245 vs. SB 417 split: why Montana’s 2025 session matters

The Montana 2025 Legislative Session produced two consequential outcomes on Medicaid policy that should be understood together, not separately:

12.1 HB 245 expanded the permanence of WHO is covered

HB 245 (Rep. Ed Buttrey, signed March 27, 2025) eliminated the recurring sunset that had accompanied Montana Medicaid expansion since the 2015 enactment. Before HB 245, Montana’s HELP Program was subject to legislative reauthorization on a multi-year cadence — each reauthorization fight was a moment of churn risk for the 75,318 enrollees. HB 245 removed that churn by making the expansion non-sunsetting.

Montana is the first state to convert a previously sunset-conditioned Medicaid expansion into a non-sunsetting permanent program. Other states adopted expansion as a permanent program from the start (most ACA-expansion states); Montana’s 2015 expansion was politically negotiated with a sunset clause that required legislative renewal. HB 245 ended that arrangement.

Operational impact for GLP-1 coverage: HB 245 eliminated a category of administrative churn that affected the 75,318 expansion enrollees, but it did NOT touch the pharmacy benefit. The categorical AOM exclusion at the DPHHS Pharmacy Program level was unchanged. A new June 2025 expansion enrollee has the same exclusion as a long-tenured traditional Medicaid beneficiary — HB 245 made the coverage relationship permanent but did not add anti-obesity drugs to the formulary.

12.2 SB 417 would have expanded WHAT is covered — and died 11-1

SB 417 (Sen. Ellie Boldman, D — District 47, Missoula) was titled verbatim “Generally revise laws relating to insurance coverage relating to obesity prevention.” It would have mandated state-regulated insurance coverage for anti-obesity medications, including in Medicaid. The bill represented the first Montana legislative attempt to mandate AOM coverage.

On March 1, 2025, the Senate Business, Labor and Economic Affairs Committee tabled SB 417 on an 11-1 vote. The bill formally died in process on May 23, 2025. The 11-1 margin is decisive in committee context — only one vote of dissent against tabling indicates broad opposition rather than narrow partisan or fiscal-only resistance.

12.3 Why the split matters for readers

The clean WHO-vs-WHAT split tells the policy story of Montana Medicaid in 2025:

• For 75,318 expansion enrollees: HB 245 means your Medicaid eligibility is no longer at recurring sunset risk. Your coverage relationship with the state is permanent unless future legislation reverses HB 245.
• For anyone seeking anti-obesity drug coverage: SB 417’s death means the categorical AOM exclusion stands. Wegovy, Zepbound, Saxenda, Imcivree, Qsymia, Contrave, orlistat, and phentermine remain excluded for obesity. T2D-indicated GLP-1 use remains covered with PA via MPQH. CV/MASH/OSA carve-outs are UNVERIFIED pending direct MPQH PDF download.
• For the 2027 session: a refile of the SB 417 framework is historically likely. The 11-1 vote suggests refile success requires substantial committee-membership shift or a fundamentally different policy frame (e.g., narrow CV-only mandate rather than broad obesity-prevention mandate).
• No other state in the 50-state series ran a parallel WHO-vs-WHAT split this cleanly in a single session. Vermont’s 2024 H.765/S.164 stalled but Vermont did not pair the stall with an expansion-permanence enactment. Maine’s 2025 LD 480 reported Ought-Not-To-Pass but Maine did not pair the OP with an expansion-permanence enactment. Montana ran both in the same 90-day legislative session and produced an unambiguous policy signal: permanent WHO, unchanged WHAT.

12.4 The fiscal context: AOM cost estimates across peer states

Montana did not publish a specific SB 417 fiscal estimate in publicly accessible documents we could locate during this verification. However, peer-state estimates provide a calibration range:

• Vermont — DVHA estimated H.765/S.164 (2024) at “approximately $75 million annually in drug costs within a few years” (VtDigger, February 18, 2024).
• Nebraska — LB907 (2024) fiscal note totaled $42.4 million.
• Maine — LD 480 (2025) fiscal note totaled $42-$53 million.

Montana’s smaller Medicaid population (~210,942 total vs. Vermont’s 178,842, Nebraska’s ~370,000, Maine’s ~390,000) would proportionately suggest a fiscal note in the $20-$50M annual range. The 11-1 committee vote suggests fiscal concerns combined with broader policy resistance produced the decisive tabling.

13. End-to-end prescriber workflow for Montana Medicaid GLP-1 PA

For prescribers writing GLP-1 prescriptions for Montana Medicaid beneficiaries, the operational workflow is:

1. Determine the indication and verify coverage gating.
   • T2D-indicated (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Exenatide): standard PA via MPQH. Document T2D diagnosis (ICD-10 E11.x), HbA1c, prior medication trials.
   • Established CV / MASH / OSA indication: call MPQH at (800) 395-7961 and request the current Wegovy and Zepbound PA criteria PDFs directly. The MPQH-posted URLs are UNVERIFIED pending direct download.
   • Obesity-only without CV/MASH/OSA: NOT COVERED. Refer the patient to manufacturer cash-pay (NovoCare, LillyDirect), patient assistance programs (Novo Nordisk PAP, Lilly Cares), or LegitScript-approved compounded telehealth.
2. Complete the “Request for Drug Prior Authorization” form. The single PA form is at medicaidprovider.mt.gov/docs/forms/prescripdrugpriorauthreq.pdf. Document:
   • Patient name, Medicaid ID, date of birth
   • Prescriber NPI, contact information, signature
   • Drug name, strength, formulation, days’ supply
   • ICD-10 diagnosis code(s)
   • BMI to one decimal place (where relevant for any UNVERIFIED carve-out)
   • Clinical rationale and indication-specific supporting evidence
   • Prior medication trial history with outcomes (for step-therapy override)
3. Fax to MPQH at (800) 294-1350 or (406) 513-1928. Backup phone: (800) 395-7961 or (406) 443-6002. Mail address for non-fax submissions: MPQH Drug PA Unit, P.O. Box 5119, Helena, MT 59604.
4. Expect immediate decision turnaround. Per the Montana Medicaid Prescription Drug Program Manual verbatim: “Requests are typically decided immediately; special circumstances receive decisions within 24 hours.”
5. For denials: call MPQH at (800) 395-7961 to verify denial rationale. Re-submit with stronger evidence if the denial is documentation-deficient. For substantive criteria-based denials, advise the beneficiary to file the administrative hearing request with DPHHS Office of Administrative Hearings within 15 days (or 30 days where the longer window applies). Continuation of benefits is automatic unless the beneficiary opts out.
6. For provider-side disputes: file the Administrative Review Request to the Department within 30 days of mailing of the written determination per Mont. Admin. R. 37.5.310. If administrative review denies, file the Fair Hearing Request within 30 days of the administrative review determination.

Pharmacy claim adjudication: the MPQH PA approval permits the pharmacy to submit a claim through the Montana Medicaid pharmacy point-of-sale system. The pharmacy will receive an approval message keyed to the PA number; the beneficiary pays no copay for covered drugs under Montana Medicaid (federal copay rules apply per 42 CFR 447.50-447.57). For AI/AN beneficiaries served by IHS or tribal 638 pharmacies, the same approval flow applies with 100% FMAP back to the state.

14. Patient scenario narratives

The following hypothetical scenarios illustrate how the Montana Medicaid AOM exclusion and the PA process operate in practice. These are illustrative scenarios, not specific patient cases.

14.1 Scenario: Established T2D patient on Ozempic

A 54-year-old Montana Medicaid beneficiary with Type 2 diabetes (ICD-10 E11.9), HbA1c 8.4%, BMI 34, and established Ozempic 1 mg weekly for the past 18 months. Patient relocates from a state with positive coverage to Montana. Workflow: patient’s new PCP submits the “Request for Drug Prior Authorization” form to MPQH documenting the T2D diagnosis, recent HbA1c, prior metformin trial outcome, current Ozempic dosing, and clinical rationale. MPQH adjudicates the request — turnaround verbatim “typically decided immediately; special circumstances receive decisions within 24 hours.” Approval is expected for T2D-indicated Ozempic use. Patient continues therapy without interruption. The categorical AOM exclusion does NOT apply here because the indication is T2D, not weight reduction.

14.2 Scenario: Patient with obesity but no T2D, no CVD, no OSA, no MASH

A 38-year-old Montana Medicaid beneficiary with BMI 36, no Type 2 diabetes, no established cardiovascular disease, no sleep-study-documented OSA, no MASH. Patient wants Wegovy or Zepbound for weight management. Workflow: prescriber explains the categorical AOM exclusion. Wegovy and Zepbound for obesity are NOT covered. The DPHHS Pharmacy Program lists “weight-loss medications” in the Not Covered bucket; the Montana Medicaid Prescription Drug Program Manual confirms “The program explicitly does not reimburse for drugs prescribed for weight reduction.” Practical alternatives: (1) NovoCare Wegovy cash-pay tiered pricing; (2) LillyDirect Zepbound vials cash-pay; (3) LillyDirect Foundayo (orforglipron, FDA-approved April 1, 2026) at $149/month self-pay; (4) Novo Nordisk PAP or Lilly Cares income-tested support; (5) LegitScript-approved compounded telehealth.

14.3 Scenario: Patient with established CVD and obesity, no T2D

A 62-year-old Montana Medicaid beneficiary with BMI 31, prior myocardial infarction (ICD-10 I25.2 documenting old MI), no Type 2 diabetes. Patient’s cardiologist proposes Wegovy for cardiovascular risk reduction under the SELECT-trial-derived indication. Workflow: prescriber calls MPQH at (800) 395-7961 to request the current Wegovy PA criteria PDF directly. The MPQH posted URL is at mpqhf.org/download/25789/ but the content is UNVERIFIED in this article pending direct download. Assuming the criteria mirror federal Medicaid rebate obligations and peer-state structures (e.g., Vermont’s Wegovy MACE carve-out at BMI > 27 with established CVD), the prescriber should document the prior MI with cardiology consult notes and objective imaging (ECG, cath, MRI), the BMI > 27 threshold, the absence of T2D, the lifestyle counseling, and the “not for weight loss only” attestation. PA submission via the master “Request for Drug Prior Authorization” form to MPQH. If the carve-out is operational, approval is expected; if the carve-out is not operationally available in Montana as of May 15, 2026, the patient’s coverage falls back to cash-pay alternatives.

14.4 Scenario: AI/AN Medicaid beneficiary at a tribal 638 pharmacy

A 45-year-old AI/AN Medicaid beneficiary served by a tribal 638-contract pharmacy on a Montana reservation. Patient has Type 2 diabetes and wants to start Mounjaro. Workflow: tribal pharmacy operates under the Montana Medicaid pharmacy benefit (the 100% FMAP applies on the back end but the formulary on the front end is the DPHHS PDL). The prescriber submits the standard PA via MPQH. The patient pays no copay. The categorical AOM exclusion does NOT apply because the indication is T2D. Whether 638-contract pharmacies have separate formulary access or AOM-coverage flexibility for any beneficiary remains UNVERIFIED; the DPHHS Tribal Consultation page and Montana Medicaid IHS Provider materials should be consulted for jurisdiction-specific guidance.

14.5 Scenario: PA denied, patient files administrative hearing

A 50-year-old Montana Medicaid beneficiary’s T2D-indicated GLP-1 PA is denied by MPQH on grounds that the prior metformin trial documentation is insufficient. Workflow: (1) prescriber calls MPQH at (800) 395-7961 to verify denial rationale; (2) prescriber re-submits the PA with additional documentation (metformin start date, dose, duration, HbA1c trajectory, adverse effects or intolerance); (3) if re-submission also denies, the patient files the administrative hearing request with DPHHS Office of Administrative Hearings within 15 days of the denial notice (or 30 days where the longer window applies); (4) continuation of benefits is automatic unless the patient opts out; (5) the hearing is held via Zoom; (6) the hearing officer renders a written proposed decision within 90 calendar days; (7) the patient may seek free representation guidance via Cover Montana or Montana Lawhelp.

15. UNVERIFIED items — flagged honestly

Per Weight Loss Rankings’ YMYL 125% accuracy standard, the following items are flagged as UNVERIFIED rather than fabricated. These are gaps in the publicly available Montana Medicaid primary sources that readers should verify independently:

1. Wegovy MPQH PA criteria PDF (BMI thresholds, ICD-10 codes, prerequisites, age gates). MPQH has posted a Wegovy PA criteria document at mpqhf.org/download/25789/ but the document returned as redirect/binary in WebFetch on May 15, 2026. Direct download is required for verbatim quotation. The Honest Care tracker (secondary source) classifies Montana as Tier 2 limited with “BMI 35+ with multiple comorbidities, PA approval rates 30-55%,” but this characterization is NOT verified against the actual MPQH criteria PDF. Until the PDF is directly downloaded and quoted verbatim, all carve-out specifics are UNVERIFIED.
2. Zepbound MPQH PA criteria PDF (OSA vs. obesity indication split, AHI thresholds, CPAP prerequisites, weight-loss milestones at reauthorization). MPQH has posted a Zepbound PA criteria document at mpqhf.org/download/26184/ but the document also returned as redirect/binary in WebFetch on May 15, 2026.
3. May 2026 PDL specific GLP-1 entries. Preferred vs. non-preferred status, T2D vs. CV vs. OSA carve-back-in, quantity limits, and step-therapy prerequisites for Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, and Exenatide are UNVERIFIED due to PDL PDF binary corruption in WebFetch.
4. Live current MT Medicaid total enrollment May 2026. The 210,942 figure (October 2025, healthinsurance.org) is the most current verified total. The DPHHS Medicaid Enrollment Dashboard (Tableau dashboard) provides live data but the May 2026 figure was not extracted in this verification.
5. MT-specific expedited appeal timeline. The federal floor under 42 CFR 431.244(f)(2) is 72 hours for cases involving immediate or serious threat to life or health. Montana-specific expedited cycle time language was not located in the DPHHS Office of Administrative Hearings FAQ or the CMA 1505-1 Combined Medicaid Fair Hearings document on May 15, 2026.
6. Tribal 638-contract pharmacy AOM exclusion parity. Whether tribally operated 638-contract pharmacies have separate formulary access or AOM-coverage flexibility distinct from the DPHHS PDL is not addressed in publicly accessible Montana Medicaid IHS Provider materials.
7. Wegovy CV / MASH / pediatric / Zepbound OSA carve-back-in implementation status. Federal Medicaid rebate rule obligates Wegovy CV coverage at minimum, but Montana’s implementation of that obligation through the DPHHS PDL is UNVERIFIED. SELECT, MASH, OSA, and pediatric (ages 12+) carve-back-in pathways may exist via the MPQH PA criteria PDFs (items 1-2 above) but cannot be confirmed without direct PDF download.

If you encounter any of these gaps in practice — particularly direct download of the MPQH Wegovy or Zepbound PA criteria PDFs — please contact us and we will update this article with verified primary-source language in a subsequent revision.

16. How Montana Pattern #46 fits the 50-state series

Montana (Pattern #46) is a clean categorical-exclusion state with a distinctive PCCM-not-MCO architecture and a clean 2025-session WHO-vs-WHAT legislative split (HB 245 expanded permanence of WHO is covered; SB 417 died on the question of WHAT is covered for AOM). The 46-state series to date documents the following coverage-architecture groups, with Montana placed in the categorical-exclusion-without-operationalized-carve-outs group:

16.1 Montana vs. Maine (Pattern #39) — closest peer

Both Montana and Maine paired a categorical AOM exclusion with a 2025-session legislative reform attempt that failed:

• Maine LD 480 reported Ought-Not-To-Pass on March 20, 2025 (definitive committee disposition).
• Montana SB 417 tabled 11-1 March 1, 2025 and died May 23, 2025 (soft fail without definitive Ought-Not-To-Pass disposition).

Distinctive differences:

• Architecture: Montana is PCCM-not-MCO (Passport to Health since 1993, BCBSMT expansion contract ended end of 2017). Maine is FFS-dominant with PCMH and health-home programs supplementing FFS.
• PA processor: Montana uses MPQH (a non-profit QIO). Maine uses Optum (a commercial PBM).
• Carve-outs: Maine has Wegovy MACE and Zepbound OSA carve-outs operationalized. Montana’s carve-outs are UNVERIFIED as of May 15, 2026 due to MPQH PDF download blockers.
• IHS overlap: Montana has one of the largest per-capita IHS Medicaid populations in the country (~20,091 AI/AN expansion enrollees April 2023). Maine’s Wabanaki/Passamaquoddy population is smaller.
• Expansion permanence: Montana’s HB 245 (signed March 27, 2025) made expansion non-sunsetting (first state to do so). Maine’s expansion (via ballot Question 2 in 2017) has been operationally durable but did not face a comparable sunset-elimination question in 2025.

16.2 Montana vs. Vermont (Pattern #41) — inverse architecture

Montana and Vermont represent inverse architectures in the categorical-exclusion group:

• Carve-out depth: Vermont has three fully operationalized FDA-label carve-outs (Wegovy MACE + Wegovy MASH + Zepbound OSA) with drug-specific PA forms. Montana’s carve-out posture is UNVERIFIED — MPQH has posted Wegovy and Zepbound PA criteria PDFs but the documents are not directly readable as of May 15, 2026.
• PA processor: Vermont uses Optum (commercial PBM, acquired Change Healthcare 2022). Montana uses MPQH (non-profit QIO).
• PDL architecture: Vermont publishes one unified PDL (April 17, 2026 effective). Montana publishes a PDL twice annually (January 15, 2026 and May 1, 2026 effective).
• Legislative reform: Vermont’s H.765/S.164 (2024) stalled with DVHA’s $75M annual fiscal estimate. Montana’s SB 417 (2025) tabled 11-1 in committee (broader committee opposition than fiscal-only).

17. Cash-pay and manufacturer-program landscape for excluded indications

Montana Medicaid beneficiaries who do not qualify for T2D-indicated GLP-1 coverage and have no operational CV/MASH/OSA carve-out access must rely on out-of-pocket and manufacturer-program pathways. The 2026-05-15 NovoCare and LillyDirect verifications produced the following operational landscape:

17.1 NovoCare Wegovy direct pricing (Novo Nordisk)

• 0.25 mg / 0.5 mg / 1.0 mg / 1.7 mg pen-injector: tiered cash-pay pricing $199-$349 per 28-day supply depending on dose. Verify current dose-specific pricing at novocare.com.
• HD (high-dose) pen-injector: $399 per 28-day supply.
• Oral semaglutide tablets (for CV indication; not yet broadly available for obesity): $149 per 30-day supply.
• Direct-to-home shipping: available to Montana addresses. Verify with the manufacturer for rural-address coverage.

17.2 LillyDirect Zepbound and Foundayo direct pricing (Eli Lilly)

• Zepbound vials: $299-$699 per 28-day supply depending on dose (single-dose vials, self-administered).
• Foundayo (orforglipron) oral tablets: $149 per 30-day supply self-pay. Foundayo was FDA-approved April 1, 2026 and is the first FDA-approved oral non-peptide GLP-1 receptor agonist for chronic weight management.
• Mounjaro (T2D-only indication): LillyDirect cash-pay tiers available; coverage in Montana Medicaid is via the T2D-indicated GLP-1 PA pathway.
• Direct-to-home shipping: available to Montana addresses via lillydirect.lilly.com.

17.3 Manufacturer patient-assistance programs (income-tested)

• Novo Nordisk Patient Assistance Program (PAP): income-tested support for Wegovy, Saxenda, Victoza, Ozempic, Rybelsus, and other Novo Nordisk products. Application at novocare.com/patient-assistance-program.
• Lilly Cares Foundation: income-tested support for Zepbound, Mounjaro, Trulicity, and other Lilly products. Application at lillycares.com.
• Eligibility considerations: PAPs typically require income at or below 300-400% FPL, no other insurance coverage for the requested drug, and US residency. Montana Medicaid beneficiaries who do not qualify for Medicaid coverage of the requested drug may still qualify for PAP support; the manufacturer programs and Medicaid are coordinated to avoid duplication.

17.4 LegitScript-approved compounded telehealth

• Compounded semaglutide: typical market pricing $99-$199 per month as of May 2026 via LegitScript-approved telehealth platforms.
• Compounded tirzepatide: typical market pricing $149-$249 per month.
• FDA compounding-resolved status: FDA declared tirzepatide compounding-resolved in October 2024 and semaglutide compounding-resolved in February 2025. New compounded prescriptions for these molecules now require documented patient-specific clinical need beyond the previous shortage justification. Patients pursuing this path should ensure their telehealth platform documents the patient-specific clinical justification.
• LegitScript verification: only use LegitScript-approved (or equivalent third-party-verified) telehealth platforms. Unverified online pharmacies may dispense substandard or adulterated product; Montana rural patients are at elevated risk given limited in-person dispensing options.
• Montana telehealth licensing: prescribers writing compounded prescriptions to Montana patients must hold Montana medical licensure or rely on a Montana-licensed delegate prescriber per Montana Board of Medical Examiners regulations.

17.5 Total annual cash-pay cost calibration

For a Montana patient who would otherwise be a Medicaid GLP-1 obesity candidate, annual cash-pay costs (excluding office visits, lab work, and other ancillary care) calibrate as follows:

• NovoCare Wegovy 1.0 mg / 1.7 mg standard dose: $249-$349/month × 12 = $2,988-$4,188 annually.
• LillyDirect Zepbound 5 mg / 10 mg vial: $349-$549/month × 12 = $4,188-$6,588 annually.
• LillyDirect Foundayo (orforglipron) 6 mg / 12 mg / 36 mg tablet: $149/month × 12 = $1,788 annually.
• LegitScript-approved compounded semaglutide: $99-$199/month × 12 = $1,188-$2,388 annually.
• LegitScript-approved compounded tirzepatide: $149-$249/month × 12 = $1,788-$2,988 annually.

These costs are substantial for a Medicaid-eligible population (incomes by definition below 138% FPL for the expansion segment). The fiscal-policy framing that drove SB 417’s 11-1 death is mirrored on the patient side: the cost of GLP-1 access without coverage is a meaningful share of household budget. Montana’s sparse-geography population is particularly affected because mail-order pharmacy delivery is the primary access route, and rural delivery surcharges can add 5-15% to the listed manufacturer prices in some cases.

18. What Montana Medicaid beneficiaries should do right now

If you have Type 2 diabetes: T2D-indicated GLP-1 receptor agonists are covered with PA via MPQH. Ask your prescriber to submit the “Request for Drug Prior Authorization” form (medicaidprovider.mt.gov/docs/forms/prescripdrugpriorauthreq.pdf) to MPQH at fax (800) 294-1350. Document the T2D diagnosis with ICD-10 (E11.x), baseline and recent HbA1c, prior metformin and second-line class trials, and the clinical rationale for GLP-1 selection. Turnaround verbatim: “Requests are typically decided immediately; special circumstances receive decisions within 24 hours.”

If you have an established CV / MASH / OSA indication and your prescriber suspects a carve-out pathway may exist: ask the prescriber to call MPQH at (800) 395-7961 and request the current Wegovy and Zepbound PA criteria PDFs directly. The MPQH-posted URLs (mpqhf.org/download/25789/ for Wegovy and mpqhf.org/download/26184/ for Zepbound) are operational but the content is UNVERIFIED in this article due to download blockers as of May 15, 2026.

If you do not have a T2D diagnosis or an established CV / MASH / OSA indication: Montana Medicaid will not cover GLP-1 receptor agonists for obesity. Practical paths: (1) NovoCare Wegovy cash-pay ($199-$349/month depending on dose; HD pen at $399/month; oral semaglutide tablets at $149/month); (2) LillyDirect Zepbound vials at $299-$699/month; (3) LillyDirect Foundayo (orforglipron, FDA-approved April 1, 2026) at $149/month; (4) patient assistance programs (Novo Nordisk PAP, Lilly Cares) for income-tested support; (5) LegitScript-approved compounded telehealth at $99-$199/month for semaglutide and $149-$249/month for tirzepatide (with the FDA compounding-resolved caveat for both molecules).

If you are an AI/AN Medicaid beneficiary served by an IHS, tribal 638, or urban Indian pharmacy: the categorical AOM exclusion still applies despite 100% FMAP. T2D-indicated coverage operates the same way as for non-AI/AN beneficiaries. For carve-out questions specific to tribal 638 pharmacies, contact the DPHHS Tribal Consultation office or the Montana Medicaid IHS Provider line.

If you live in rural Montana with limited specialist access: PCP-issued GLP-1 prescriptions are typically the most accessible route. Mail-order pharmacy delivery is operationally important — verify in-network status with MPQH at (800) 395-7961. Telehealth specialist consultation via licensed Montana providers can substitute for in-person endocrinology or sleep medicine visits.

If your PA is denied: do not give up after the first denial. Call the MPQH Drug PA Unit at (800) 395-7961 to verify denial rationale — many denials are documentation deficiencies recoverable via re-submission. If the denial is criteria-based, re-submit with stronger clinical evidence. If re-submission fails, file the beneficiary-side administrative hearing request within 15 days (or 30 days in cases where the longer window applies). Continuation of benefits is automatic unless you opt out. Contact Cover Montana or Montana Lawhelp for representation guidance.

If you want to influence the policy: SB 417 (Sen. Ellie Boldman’s AOM mandate) died 11-1 in committee on March 1, 2025 and formally on May 23, 2025. Montana’s legislative sessions are biennial; the next session convenes January 2027. Contact your state senator and representative before the 2027 session to advocate for a refile and broader committee support for the AOM mandate framework.

19. Key takeaways for Montana Medicaid GLP-1 access

1. The categorical exclusion is verbatim and bundled. The DPHHS Pharmacy Program lists “weight-loss medications” in the Not Covered bucket alongside fertility drugs, cosmetic treatments, erectile dysfunction drugs, and non-formulary OTC drugs. The Montana Medicaid Prescription Drug Program Manual reinforces with: “The program explicitly does not reimburse for drugs prescribed for weight reduction.” Two verbatim statements at two different DPHHS-owned URLs eliminate ambiguity.
2. HB 245 expanded permanence of WHO is covered. Signed March 27, 2025 by Gov. Greg Gianforte. Eliminated the recurring sunset that had accompanied Medicaid expansion since 2015. Montana is the first state to convert a previously sunset-conditioned expansion into a non-sunsetting permanent program.
3. SB 417 died 11-1 on the question of WHAT is covered for AOM. Tabled March 1, 2025 by the Senate Business, Labor and Economic Affairs Committee. Died May 23, 2025. First Montana legislative attempt at AOM coverage mandate. Sen. Ellie Boldman likely to refile in 2027.
4. Architecture is PCCM (Passport to Health), not capitated MCOs. Montana is one of approximately 6 states still using PCCM rather than full-risk MCO managed care. BCBSMT expansion contract ended end of 2017; no MCO has been contracted since. One statewide PDL via DPHHS + MPQH.
5. MPQH is a non-profit QIO, not a commercial PBM. Drug PA Unit: phone (800) 395-7961; fax (800) 294-1350. PA appeals escalate directly to DPHHS without commercial-PBM intermediary.
6. PA turnaround is verbatim “typically decided immediately; special circumstances receive decisions within 24 hours.” One of the fastest documented PA turnaround windows in the 50-state series.
7. Appeals architecture has tight beneficiary windows. Most appeals must be filed within 15 days; some allow 30 days; 90-day outer cap from adverse notice. Provider-side per Mont. Admin. R. 37.5.310: 30-day Administrative Review Request, 30-day Fair Hearing Request, 90-day hearing-officer decision. Continuation of benefits is automatic unless the claimant opts out.
8. One of the largest per-capita IHS Medicaid populations in the country. ~20,091 AI/AN expansion enrollees (April 2023). IHS facilities draw 100% FMAP but the AOM exclusion still applies.
9. Sparse-geography access dominates. Montana ranks among the lowest US states for endocrinologist and bariatric medicine density. Mail-order pharmacy is operationally important even where coverage exists.
10. Carve-outs (Wegovy CV / MASH / Zepbound OSA) are UNVERIFIED. MPQH has posted PA criteria PDFs at mpqhf.org/download/25789/ (Wegovy) and mpqhf.org/download/26184/ (Zepbound) but the documents returned as redirect/binary in WebFetch on May 15, 2026. Direct PDF download is required for verbatim quotation. Until then, all carve-out specifics are flagged UNVERIFIED honestly.

Related coverage

• Hawaii Med-QUEST GLP-1 Coverage (Pattern #50 CAPSTONE / SERIES COMPLETE) — closest live-2026-legislative-session peer to MT: where MT SB 417 (Sen. Ellie Boldman D, AOM mandate) died 11-1 in Senate committee 3/1/2025 and was followed by HB 245 making expansion permanent on the same Gianforte signature, HI SB 3195 (Sen. Kurt Fevella R-Ewa Beach, bipartisan, 2026 Regular Session) remains live with sponsor personal angle (“he takes Mounjaro for diabetes and has lost about 80 pounds”) and would scrap the categorical exclusion AND prohibit PA. HI carve-outs UNVERIFIED (binary-PDF MCO formularies) vs. MT’s clean categorical exclusion in DPHHS Pharmacy Program “Not Covered” bucket. HI 5-MCO mandatory managed care under 32-year 1115 demonstration vs. MT PCCM (Passport to Health since 1993). Pattern #50 closes the 50-state series
• Wyoming Medicaid GLP-1 Coverage (Pattern #47) — closest contiguous Mountain-West peer with codified categorical exclusion and three FDA-label carve-ins: WY uses “Anorexiant products” in WDH Pharmacy Services Manual Revision 27 (eff. April 15, 2026) page 8 (MT uses “weight-loss medications” in DPHHS Pharmacy Program “Not Covered” bucket); WY has three concretely-codified FDA-label carve-ins (Wegovy SELECT/CV verbatim FDA label adoption, Wegovy MASH, Zepbound OSA — LEAST restrictive OSA carve-in in categorical cohort, no CPAP prerequisite) while MT’s carve-out implementation is UNVERIFIED. WY uses FFS-only with WYhealth CME (not capitated) + OptumRx as pharmacy benefit administrator after April 15, 2026 migration; MT uses PCCM (Passport to Health since 1993) + Mountain-Pacific Quality Health (MPQH non-profit QIO). MT made expansion permanent (HB 245 signed March 27, 2025); WY remains non-expansion (2026 expansion defeated 7-23 and 5-26). MT SB 417 died 11-1 in committee 3/1/2025; WY had no AOM legislation in 2024-2026. WY ~59,714 enrollment (smallest US state by population); MT ~210,942
• Alaska Medicaid GLP-1 Coverage (Pattern #49) — closest peer architecturally to MT in the sparse-geography categorical-exclusion-with-tribal-health-overlap subgroup: both AK and MT have categorical AOM exclusions; MT codifies the exclusion verbatim (“weight-loss medications” in the DPHHS Not Covered bucket) while AK operates by PDL absence (Wegovy / Zepbound / Saxenda absent from any class of the March 1, 2026 PDL); MT uses MPQH (non-profit QIO) for PA processing, AK uses Prime Therapeutics Medicaid Administration (commercial PBM, formerly Magellan Rx); MT has 7 federally recognized tribes (~20,091 AI/AN expansion enrollees) while AK has 229+ federally recognized tribes with Alaska Area IHS + ANTHC operating 8 tribally managed hospitals + 72 tribal health centers + 148 village clinics; MT had decisive 2025 SB 417 rejection (11-1 March 1, 2025), AK has no comparable AOM-mandate bill identified; AK is FFS-only with no MCOs, MT uses PCCM (Passport to Health) overlay on FFS
• Vermont Medicaid GLP-1 Coverage (Pattern #41) — inverse architecture in the categorical-exclusion group: VT has three operationalized carve-outs (Wegovy MACE + Wegovy MASH + Zepbound OSA) via drug-specific PA forms; MT’s carve-outs UNVERIFIED
• North Dakota Medicaid GLP-1 Coverage (Pattern #44) — adjacent Great Plains state with middle-ground “covered for everything except obesity” architecture: ND covers Wegovy MACE + Wegovy MASH + Zepbound OSA (most restrictive OSA carve-out in series) + Ozempic/Victoza no-PA for antipsychotic-induced weight gain + Imcivree + low-cost AOMs without PA but NOT Wegovy/Zepbound/Saxenda for standalone obesity; both MT (SB 417, 11-1 in committee) and ND (HB 1451, 12-81 on House floor) had decisive 2025 legislative rejections; ND uses FFS-dominant + BCBSND-only expansion (1915(b) waiver), MT uses PCCM (Passport to Health)
• South Dakota Medicaid GLP-1 Coverage (Pattern #45) — closest peer to MT in the functional-AOM-exclusion group: also sparsely populated with meaningful tribal health overlap, also FFS-architecture, but SD operates an exclusion by ABSENCE (no codified categorical sentence anywhere; the OptumRx SD-specific GLP-1 PA form pre-codes ONLY T2D as the indication checkbox) vs. MT’s explicit codification in the DPHHS Pharmacy Program “Not Covered” bucket and Prescription Drug Program Manual; SD ballot-initiative expansion (Amendment D 2022) with uniquely constitutionalized 90% FMAP trigger on the Nov 3, 2026 ballot (Constitutional Amendment I via HJR 5001)
• Idaho Medicaid GLP-1 Coverage (Pattern #48) — codification-vs-non-codification contrast to MT in the adjacent Mountain-West cohort: where MT codifies the categorical AOM exclusion verbatim in the DPHHS Prescription Drug Program Manual (“weight-loss medications” Not Covered bucket), ID has NO codified categorical exclusion — IDAPA 16.03.09.662 does NOT enumerate anti-obesity drugs as an excluded class. ID’s exclusion operates through PDL non-preferred status and PA criteria. Bar to administrative carve-back-in is LOWER in ID than in MT. MT uses PCCM (Passport to Health); ID’s Healthy Connections PCCM terminated 12/31/2025 leaving ID FFS-only for traditional Medicaid with comprehensive MCO transition delayed to 1/1/2030. Active ID legislative repeal trajectory (HB 138 / HB 345 / HB 913) + Office of Group Insurance dropped GLP-1 obesity coverage Nov 1, 2025
• Rhode Island Medicaid GLP-1 Coverage (Pattern #40) — first state in series with active coverage + governor-proposed October 1, 2026 sunset (inverse coverage posture to MT)
• Maine MaineCare GLP-1 Coverage (Pattern #39) — closest peer in series; categorical exclusion + 2025-session legislative reform attempt that failed (LD 480 Ought-Not-To-Pass March 20, 2025)
• Nebraska Medicaid GLP-1 Coverage (Pattern #38) — categorical exclusion with 45-74 age gate + 6-month MASH prerequisite; LB907 Indefinitely Postponed
• Utah Medicaid GLP-1 Coverage (Pattern #37) — legislative pilot-program coverage with 6/30/2026 sunset of in-lab attended PSG carve-out
• West Virginia Medicaid GLP-1 Coverage (Pattern #36) — categorical exclusion with Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs via WVU RDTP
• Mississippi Medicaid GLP-1 Coverage (Pattern #35) — only non-expansion southern positive-coverage state; SPA 23-0013 carve-back-in with pediatric ages 12+ pathway
• 50-state Medicaid GLP-1 coverage map — full series overview with pattern taxonomy
• GLP-1 insurance coverage hub — Medicare, Medicaid, and commercial coverage landscape
• GLP-1 insurance dropped coverage appeal playbook — denial-recovery patterns applicable across states

Primary sources

1. DPHHS Pharmacy Program — verbatim “weight-loss medications” Not Covered bucket
2. Montana Medicaid Prescription Drug Program Manual — verbatim “The program explicitly does not reimburse for drugs prescribed for weight reduction”
3. Montana PDL effective May 1, 2026
4. Montana PDL effective January 15, 2026
5. Montana Medicaid Prior Authorization landing
6. Drug Prior Authorization Request Form
7. Passport to Health (PCCM)
8. DPHHS Office of Administrative Hearings FAQ
9. CMA 1505-1 Combined Medicaid Fair Hearings
10. Medicaid in Montana — DPHHS legislative briefing
11. DPHHS Medicaid Enrollment Dashboard (Tableau)
12. Mont. Admin. R. 37.5.310 — provider-side appeals
13. Mont. Admin. R. 37.85.207
14. DPHHS Tribal Consultation
15. Montana Medicaid IHS Provider
16. MPQH Montana Medicaid Pharmacy hub
17. MPQH Drug Prior Authorization service
18. MPQH Pharmacy Resources (Wegovy + Zepbound PA criteria links)
19. MPQH Wegovy PA criteria — status UNVERIFIED (binary download required)
20. MPQH Zepbound PA criteria — status UNVERIFIED (binary download required)
21. Montana Bill Explorer (legmt.gov)
22. SB 417 (2025) tracker
23. KFF — Medicaid Coverage of and Spending on GLP-1s
24. Montana Free Press — Gianforte signs HB 245 (March 28, 2025)
25. healthinsurance.org Montana — enrollment and program overview
26. Montana Lawhelp — fair hearings FAQ
27. Cover Montana — fair hearings and administrative review
28. MT Budget & Policy Center — Medicaid Expansion in Indian Country